Tirzepatide vs. retatrutide: what the muscle loss claims get wrong

What did @nickolespeps actually say?

The creator argued that retatrutide ("reda") is superior to tirzepatide ("turd zeptide") because it hits three receptors instead of two, and that this extra receptor action "speeds up your metabolism" while helping the body "maintain your muscle mass and only focus on the fat." Tirzepatide, they claimed, "slows down your metabolism because you're not eating as much and you're not moving as much." These are specific mechanistic claims, not just personal anecdotes, and they deserve scrutiny.

To be clear about what's being compared: tirzepatide is an FDA-approved dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor agonism as the third target. That part is accurate pharmacology. The conclusions drawn from it are where things get complicated.

Does the science back this up?

Partially, but the creator oversimplifies in ways that matter. The glucagon receptor component of retatrutide does appear to increase energy expenditure, which is distinct from just suppressing appetite. A phase 2 trial (Jastreboff et al., 2023, NEJM) showed retatrutide produced up to 24.2% mean weight loss at 48 weeks, which is striking. But calling this "speeding up your metabolism" as a clean summary glosses over the mechanisms and the trade-offs.

On the tirzepatide side, a metabolic adaptation effect is real, but it is not unique to tirzepatide. Any significant caloric restriction reduces resting metabolic rate. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed impressive fat loss with tirzepatide, but also noted lean mass loss, consistent with most GLP-1 class drugs. The creator frames this as a tirzepatide-specific flaw. It is not.

What did they get wrong, and what did they get right?

Credit where it's due: the receptor count is correct. Retatrutide does target GLP-1, GIP, and glucagon receptors. The glucagon agonism does appear to drive thermogenesis and energy expenditure beyond what appetite suppression alone explains. That is real science, not TikTok fiction.

What they got wrong is the framing that tirzepatide uniquely "slows your metabolism." Metabolic adaptation happens with caloric restriction broadly. It happened with semaglutide, liraglutide, and it will likely happen with retatrutide too, since retatrutide also dramatically reduces caloric intake. The creator presents this as a tirzepatide-specific defect when it is a class-wide phenomenon tied to energy deficit, not to receptor count.

The muscle mass claim is also overstated. There is currently no published head-to-head trial comparing lean mass preservation between tirzepatide and retatrutide. Retatrutide's glucagon component may support metabolic rate, but "only focus on the fat" is marketing language, not a clinical finding. Research on resistance training combined with GLP-1 therapy (Cava et al., 2017, Advances in Nutrition) consistently shows that exercise, not receptor count, is the primary driver of lean mass preservation during weight loss.

What should you actually know?

Retatrutide is still in clinical trials as of this writing. It is not FDA-approved. Anyone accessing it today is doing so through compounded or research-grade channels, and no compounded peptide is equivalent to a pharmaceutical-grade approved drug. Full stop.

The metabolic slowdown during weight loss is not a bug specific to tirzepatide. It is a feature of losing a significant percentage of body weight, regardless of how you get there. The clinical question worth asking your provider is whether adding resistance training and adequate protein intake, which have actual evidence behind them, can offset lean mass loss on any GLP-1 class therapy.

Retatrutide's phase 2 data is genuinely promising and the triple-agonist mechanism is scientifically interesting. But "speeds up your metabolism and only burns fat" is a level of precision that the current evidence does not support. Phase 3 trials are ongoing. We do not have the long-term safety or body composition data yet to make confident comparisons to tirzepatide.

The bottom line

This video gets the receptor pharmacology roughly right but builds too much on top of it. The metabolism and muscle mass claims are extrapolations from mechanism, not from clinical outcomes data. If you are deciding between GLP-1 class medications, that conversation belongs with a licensed prescriber who has access to your health history, not a TikTok comparison video with 95,000 views.